
    
      The primary effectiveness hypothesis is to demonstrate that the GORE VIABAHN® Endoprosthesis
      with PROPATEN Bioactive Surface will extend the period of target lesion primary patency as
      compared to PTA.

      The primary safety hypothesis is to demonstrate that the proportion of subjects remaining
      free from major device, procedure, and treatment site-related adverse events through 30 days
      post-procedure in the GORE® VIABAHN® Device group is not inferior to that of the PTA group.
    
  